p53肽在肿瘤免疫治疗中的研究进展
被引量：1
Research Progress in Anti-cancer Immunotherapy of Wild-type p53 Peptides
摘要
体内外研究证实wtp53肽段可诱导特异性的CD8+T细胞和CD4+T细胞,因此,wtp53肽在肿瘤免疫治疗中得到广泛应用,并且,一些表位疫苗的抗肿瘤免疫治疗已进入Ⅰ、Ⅱ期临床研究。全文就近年来wtp53在肿瘤细胞中的免疫原性、新表位的确定以及这些新表位在临床肿瘤治疗中的作用进行阐述。
出处
《肿瘤学杂志》
CAS
2011年第8期630-632,共3页
Journal of Chinese Oncology
参考文献22
-
1Farkas AM, Finn OJ . Vaccines based on abnormal self- antigens as tumor-associated antigens : immune regulation [J]. Semin Immunol,2010, 22(3) : 125-131.
-
2DeLeo AB,Whiteside TL. Development of multi-epitope vaccines targeting wild-type sequence p53 peptides [J]. Expert Rev Vaccines,2008,7(7):1031-1040.
-
3Vermeil R,Leffers N, van der Burg SH,et al. Immunolog- ical and clinical effects of vaccines targeting p53-overexpressing malignancies[J]. J Biomed Biotechnol, 2011,2011: 702146.
-
4Bueter M,Gasser M, Lebedeva T,et al.Influence of p53 on anti-tumor immunity review [J]. Int J Oncol, 2006,28(2): 519-525.
-
5Schlichtholz B, Legros Y, Gillet D , et al. The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the muta- tional hot spot [J].Cancer Res, 1992,52 (22):6380-6384.
-
6Soussi T. p53 antibodies in the sera of patients with various types of cancer: a review [J]. Cancer Res,2000,60(7): 1777-1788.
-
7Kumar S, Mohan A,Guleria R. Prognostic implications of circulating anti-p53 antibodies in lung eancer--a review [J]. Eur J Cancer Care,2009,18(3):248-254.
-
8DeLeo AB,Whiteside TL.Development of multi-epitope vaccines targeting wild-type sequence p53 peptides [J]. Expert Rev Vaccines, 2008,7(7): 1031 - 1040.
-
9Chikamatsu K,Albers A,DeLeo AB, et al. p53 (l10-124)-speeific human CD4CF-helper cells enhance in vitro generation and antitumor function of tumor-reactive CD8+T cells[J].Cancer Res, 2003,63(13):3675-8361.
-
10Ito D,Albers A,Zhao YX,et al.The wild-type sequence (wt) p53 (25-35) peptide induces HLA-DR7 and HLA- DRI 1-restricted CD4+ Th cells capable of enhancing the ex vivo expansion and function of anti-wtp53 (264- 272) peptide CD8+T cells[J].J Immunol. 2006, 177(10):6795-6803.
同被引文献12
-
1Imre M?ger,Kent Langel,Taavi Lehto,Emelía Eiríksdóttir,ülo Langel.The role of endocytosis on the uptake kinetics of luciferin-conjugated cell-penetrating peptides[J]. BBA - Biomembranes . 2011 (3)
-
2R. Vermeij,N. Leffers,S. H. van der Burg,C. J. Melief,T. Daemen,H. W. Nijman,Peter Bretscher.Immunological and Clinical Effects of Vaccines Targeting p53-Overexpressing Malignancies[J]. Journal of Biomedicine and Biotechnology . 2011
-
3Kuldeep S. Tagore,Michael J. Lawson,Joy A. Yucaitis,Rhonda Gage,Tashia Orr,Anthony P. Shuber,Michael E. Ross.Sensitivity and Specificity of a Stool DNA Multitarget Assay Panel for the Detection of Advanced Colorectal Neoplasia[J]. Clinical Colorectal Cancer . 2003 (1)
-
4Katsumi Matsuzaki,Ken-ichi Sugishita,Koichiro Miyajima.Interactions of an antimicrobial peptide, magainin 2, with lipopolysaccharide-containing liposomes as a model for outer membranes of Gram-negative bacteria[J]. FEBS Letters . 1999 (2)
-
5de Vries Annemieke,Flores Elsa R,Miranda Barbara,Hsieh Harn-Mei,van Oostrom Conny Th M,Sage Julien,Jacks Tyler.Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function. Proceedings of the National Academy of Sciences of the United States of America . 2002
-
6Wang R F,Wang H Y.Enhancement of antitumor immunity by prolonging antigen presentation on dendritic cells. Nature Biotechnology . 2002
-
7Dong S M,Traverso G,Johnson C,et al.Detecting colorectal cancer in stool with the use of multiple genetic targets. Journal of the National Cancer Institute . 2001
-
8Patricia Roxburgh,Andreas K. Hock,Michael P. Dickens.Small molecules that bind the Mdm2 RING stabilize and activate p53. Carcinogenesis . 2012
-
9Bowne W B,Wolchok J D,Hawkins W G,Srinivasan R,Gregor P,Blachere N E,Moroi Y,Engelhorn M E,Houghton A N,Lewis J J.Injection of DNA encoding granulocyte-macrophage colony-stimulating factor recruits dendritic cells for immune adjuvant effects. Cytokines, cellular & molecular therapy . 2000
-
10任锦,钦传光,徐春兰,王秋雨,左晓佳.细胞穿膜肽作为药物载体的研究进展[J].药学学报,2010,45(1):17-25. 被引量：24
-
1辇伟奇,王志新.CEA CTL-Th融合表位疫苗的优化设计及其重组杆状病毒表达载体的构建[J].中华肿瘤防治杂志,2006,13(8):596-599. 被引量：1
-
2萨仁高娃,毕力夫,吴岩.肿瘤疫苗的研究进展[J].中国肿瘤生物治疗杂志,2009,16(6):644-647. 被引量：3
-
3李煜.微小基因疫苗抗肿瘤免疫治疗策略的设计与评价[J].国外医学（肿瘤学分册）,2002,29(2):92-94.
-
4王鹏飞,欧琴,朱珊丽,朱冠保,张丽芳.肿瘤相关抗原CEA的B细胞表位预测[J].生物医学工程与临床,2007,11(5):402-405. 被引量：3
-
5陶谦,乔彬,吕标,郑超群.人Survivin蛋白B细胞表位的初步预测[J].中华肿瘤防治杂志,2008,15(19):1451-1453.
-
6宋淑霞,郑龙,冯旭,尤红煜,张艳,刘春燕,刘福英.HLA-A0201/K^b及MAGE-3基因共转染B16细胞的制备及其在MAGE-3肿瘤疫苗评价中的作用[J].中国比较医学杂志,2007,17(8).
-
7李丹,方艳秋,谭岩,刘力华,段秀梅,许淑芬.CEA迷你基因原核表达及其诱导小鼠特异性淋巴细胞增殖的研究[J].免疫学杂志,2008,24(4):400-403. 被引量：2
-
8辇伟奇,吴玉章,王志新.大肠癌新型CEA疫苗重组杆状病毒的表达与鉴定[J].第三军医大学学报,2006,28(1):66-68. 被引量：1
-
9金劲激,丁玉杰,王冰冰,侯柏龙,张丽芳,朱冠保.MAGE-A家族抗原共同B细胞表位预测分析[J].温州医学院学报,2013,43(11):706-710. 被引量：4
